Yoram Alroy - SMDCY Founder and Pres
Founder
Mr. Yoram Alroy serves as President and NonExecutive Member of the Board of Directors at S H L Telemedicine Ltd since August 10, 2011. He was previously Chairman of the Board of Directors and President at the Company from September, 2003. He is the Founder of Shahal Medical Services Ltd., which later became S H L Telemedicine Ltd, and has served as the Company Chairman since its inception in 1987. Prior to founding S H L Telemedicine Ltd, Mr. Alroy had served as Executive Vice President and Member of the Executive Committee of IBM Israel for 18 years. After assignment at IBM Europe he was nominated to be a Member of IBM Israel Executive Committee. Mr. Alroy is also a Member of the Board of Trustees of the Ofek College for Engineering. Mr. Alroy is also a Director of the Board of Directors of Shahal Haifa, Shahal Rishon and SHL INT. since 2011.
Age | 74 |
Tenure | 13 years |
Phone | 972 3 561 2212 |
Web | http://www.shl-telemedicine.com |
SMDCY Management Efficiency
The company has return on total asset (ROA) of (11.66) % which means that it has lost $11.66 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (42.15) %, meaning that it generated substantial loss on money invested by shareholders. SMDCY's management efficiency ratios could be used to measure how well SMDCY manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 21.3 M in total debt with debt to equity ratio (D/E) of 54.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. SMDCY has a current ratio of 1.23, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist SMDCY until it has trouble settling it off, either with new capital or with free cash flow. So, SMDCY's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SMDCY sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SMDCY to invest in growth at high rates of return. When we think about SMDCY's use of debt, we should always consider it together with cash and equity.
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine systems. SMDCY [SMDCY] is traded as part of a regulated electronic trading bulletin board offered by the NASD. Management Performance
Return On Equity | -42.15 | |||
Return On Asset | -11.66 |
SMDCY Leadership Team
Elected by the shareholders, the SMDCY's board of directors comprises two types of representatives: SMDCY inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SMDCY. The board's role is to monitor SMDCY's management team and ensure that shareholders' interests are well served. SMDCY's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SMDCY's outside directors are responsible for providing unbiased perspectives on the board's policies.
Yoni Dagan, CTO | ||
Ehud BenYair, CFO | ||
Dvora Kimhi, Non-Executive Director | ||
Uzi Blumensohn, Member of the Executive Board | ||
Nehama Ronen, Independent Non-Executive Director | ||
Erez Nachtomy, Executive VP | ||
Cailong Su, Non-Executive Director | ||
Amnon Sorek, Non-Executive Director | ||
Eli Alroy, Non-Executive Director | ||
Martin Lehner, Managing Director of SHL Telemedizin Germany | ||
Elon Shalev, Non-Executive Chairman of the Board | ||
Eran Antebi, CFO | ||
Georg Oppen, Managing Director - S H L Telemedizin | ||
Yehoshua Abramovich, Board of Director | ||
Nissim Zvili, Non-Executive Independent Director | ||
Yi He, Non-Executive Director | ||
Ziv Carthy, Non-Executive Director | ||
Doron Steiger, Non-Executive Director | ||
Ronen Harel, Non-Executive Independent Director | ||
Yoav Rubinstein, Interim CEO, Head of Global Bus. Devel. and Sr. VP | ||
Xuequan Qian, Board of Director | ||
Erez Alroy, Co-CEO | ||
Amir Lerman, Non-Executive Director | ||
Shenlu Xu, Non-Executive Director | ||
Eyal Bakshi, Non-Executive Director | ||
Xuewen Wu, Chairman of the Board | ||
Arie Roth, Chief Medical Manager | ||
Yossi Vadnagra, CFO | ||
Yoram Alroy, Founder and Pres | ||
Yuval Shaked, CEO | ||
Eran Kristal, General Manager - SHL Israel | ||
Irit Alroy, CTO and Executive VP |
SMDCY Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc bb equity is not an easy task. Is SMDCY a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -42.15 | |||
Return On Asset | -11.66 | |||
Profit Margin | (55.99) % | |||
Operating Margin | (41.19) % | |||
Current Valuation | 85.98 M | |||
Shares Outstanding | 10.49 M | |||
Price To Earning | 74.59 X | |||
Price To Book | 1.49 X | |||
Price To Sales | 2.05 X | |||
Revenue | 37.88 M |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the SMDCY information on this page should be used as a complementary analysis to other SMDCY's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in SMDCY OTC BB Equity
If you are still planning to invest in SMDCY check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SMDCY's history and understand the potential risks before investing.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Commodity Directory Find actively traded commodities issued by global exchanges |